|
AU2004261229A1
(en)
*
|
2003-07-29 |
2005-02-10 |
Eisai, Inc. |
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
|
CA2556027C
(en)
|
2004-02-12 |
2015-11-24 |
Morphotek, Inc. |
Monoclonal antibodies that specifically block biological activity of a tumor antigen
|
|
CA2600505C
(en)
|
2005-03-10 |
2016-05-03 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
EP2172487A1
(en)
|
2005-04-22 |
2010-04-07 |
Morphotek Inc. |
Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
|
|
KR100694508B1
(ko)
*
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
US7943133B2
(en)
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
US7795411B2
(en)
|
2006-10-05 |
2010-09-14 |
Fred Hutchinson Cancer Research Center |
Vectors for expressing in vivo biotinylated recombinant proteins
|
|
KR20170012582A
(ko)
*
|
2006-11-02 |
2017-02-02 |
악셀레론 파마 인코포레이티드 |
Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
|
|
CA2700860C
(en)
|
2007-10-01 |
2016-07-19 |
Jonathan A. Terrett |
Human antibodies that bind mesothelin, and uses thereof
|
|
EP3103814A1
(en)
|
2007-11-26 |
2016-12-14 |
Bayer Intellectual Property GmbH |
Anti-mesothelin antibodies and uses therefor
|
|
CA2718321A1
(en)
|
2008-03-27 |
2009-10-01 |
Dimiter S. Dimitrov |
Human anti-mesothelin monoclonal antibodies
|
|
JP2010014691A
(ja)
*
|
2008-06-20 |
2010-01-21 |
Igaku Seibutsugaku Kenkyusho:Kk |
腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
|
|
US8460660B2
(en)
*
|
2009-03-24 |
2013-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
HUE036157T2
(hu)
*
|
2010-03-30 |
2018-06-28 |
Janssen Biotech Inc |
Humanizált IL-25 ellenanyagok
|
|
PE20141114A1
(es)
*
|
2010-12-20 |
2014-09-15 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados
|
|
US10233240B1
(en)
*
|
2011-04-18 |
2019-03-19 |
The Regents Of The University Of California |
Methods for treating cholestatic liver fibrosis
|
|
RU2600067C2
(ru)
|
2011-05-06 |
2016-10-20 |
Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез |
Рекомбинантный иммунотоксин, нацеленный на мезотелин
|
|
CN104220094A
(zh)
*
|
2012-02-17 |
2014-12-17 |
西雅图基因公司 |
针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
|
|
ES2706173T3
(es)
*
|
2012-03-20 |
2019-03-27 |
Biogen Ma Inc |
Anticuerpos de neutralización de JCV
|
|
DK2828284T3
(da)
|
2012-03-20 |
2019-06-11 |
Biogen Ma Inc |
Jcv-neutraliserende antistoffer
|
|
US9359447B2
(en)
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
US9409992B2
(en)
|
2012-08-21 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
CN106467573B
(zh)
*
|
2015-08-21 |
2021-05-25 |
佧珐药业有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
KR101782487B1
(ko)
*
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
US20170096485A1
(en)
*
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
|
MX389194B
(es)
*
|
2015-10-06 |
2025-03-20 |
Univ Minnesota |
Compuestos terapéuticos y métodos.
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
HRP20230528T1
(hr)
|
2016-03-22 |
2023-08-04 |
F. Hoffmann - La Roche Ag |
Bispecifične molekule t stanica aktivirane proteazom
|
|
CR20180453A
(es)
*
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
MY209117A
(en)
|
2016-04-15 |
2025-06-23 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
WO2017190148A1
(en)
*
|
2016-04-29 |
2017-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for the prevention and treatment of surgical adhesions
|
|
BR112018074453A2
(pt)
*
|
2016-05-27 |
2019-03-19 |
Abbvie Biotherapeutics Inc. |
proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
|
|
KR20190022632A
(ko)
|
2016-06-20 |
2019-03-06 |
에프-스타 베타 리미티드 |
Lag-3 결합 구성원
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP3548515B1
(en)
|
2016-12-01 |
2026-01-21 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3638295A1
(en)
|
2017-06-13 |
2020-04-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2019121906A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Specific pd-l1 binding sequences inserted in a ch3 domain
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
EP3806889A4
(en)
*
|
2018-06-18 |
2022-07-13 |
Anwita Biosciences, Inc. |
CYTOKI FUSION PROTEINS AND USES THEREOF
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR112021000282A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a cd137 e ox40
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
WO2020047501A1
(en)
|
2018-08-30 |
2020-03-05 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
WO2020081841A1
(en)
|
2018-10-19 |
2020-04-23 |
Regents Of The University Of Minnesota |
Nk engager molecules and methods of use thereof
|
|
WO2020092631A1
(en)
*
|
2018-10-31 |
2020-05-07 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
CN109705219B
(zh)
*
|
2019-01-08 |
2020-11-13 |
上海霖科生物科技有限公司 |
与间皮素结合的单克隆抗体及其制备方法
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
MX2021015533A
(es)
*
|
2019-06-19 |
2022-02-10 |
Silverback Therapeutics Inc |
Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
|
|
KR20220110231A
(ko)
|
2019-12-05 |
2022-08-05 |
씨젠 인크. |
항-αvβ6 항체 및 항체-약물 접합체
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN121038806A
(zh)
|
2023-04-25 |
2025-11-28 |
阿森纳生物科学公司 |
用于转录调控的新颖受体
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|